학술논문
Towards evidence-based response criteria for cancer immunotherapy
Document Type
article
Source
Nature Communications, Vol 14, Iss 1, Pp 1-4 (2023)
Subject
Language
English
ISSN
2041-1723
Abstract
Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.